Interferon-γ Induces Expression of MHC Class II on Intestinal Epithelial Cells and Protects Mice from Colitis

Immune responses against intestinal microbiota contribute to the pathogenesis of inflammatory bowel diseases (IBD) and involve CD4(+) T cells, which are activated by major histocompatibility complex class II (MHCII) molecules on antigen-presenting cells (APCs). However, it is largely unexplored how inflammation-induced MHCII expression by intestinal epithelial cells (IEC) affects CD4(+) T cell-mediated immunity or tolerance induction in vivo. Here, we investigated how epithelial MHCII expression is induced and how a deficiency in inducible epithelial MHCII expression alters susceptibility to colitis and the outcome of colon-specific immune responses. Colitis was induced in mice that lacked inducible expression of MHCII molecules on all nonhematopoietic cells, or specifically on IECs, by continuous infection with Helicobacter hepaticus and administration of interleukin (IL)-10 receptor-blocking antibodies (anti-IL10R mAb). To assess the role of interferon (IFN)-γ in inducing epithelial MHCII expression, the T cell adoptive transfer model of colitis was used. Abrogation of MHCII expression by nonhematopoietic cells or IECs induces colitis associated with increased colonic frequencies of innate immune cells and expression of proinflammatory cytokines. CD4(+) T-helper type (Th)1 cells - but not group 3 innate lymphoid cells (ILCs) or Th17 cells - are elevated, resulting in an unfavourably altered ratio between CD4(+) T cells and forkhead box P3 (FoxP3)(+) regulatory T (Treg) cells. IFN-γ produced mainly by CD4(+) T cells is required to upregulate MHCII expression by IECs. These results suggest that, in addition to its proinflammatory roles, IFN-γ exerts a critical anti-inflammatory function in the intestine which protects against colitis by inducing MHCII expression on IECs. This may explain the failure of anti-IFN-γ treatment to induce remission in IBD patients, despite the association of elevated IFN-γ and IBD.

Interleukin-1- and type I interferon-dependent enhanced immunogenicity of an NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletions of type I and type II interferon-binding proteins.

UNLABELLED: NYVAC, a highly attenuated, replication-restricted poxvirus, is a safe and immunogenic vaccine vector. Deletion of immune evasion genes from the poxvirus genome is an attractive strategy for improving the immunogenic properties of poxviruses. Using systems biology approaches, we describe herein the enhanced immunological profile of NYVAC vectors expressing the HIV-1 clade C env, gag, pol, and nef genes (NYVAC-C) with single or double deletions of genes encoding type I (ΔB19R) or type II (ΔB8R) interferon (IFN)-binding proteins. Transcriptomic analyses of human monocytes infected with NYVAC-C, NYVAC-C with the B19R deletion (NYVAC-C-ΔB19R), or NYVAC-C with B8R and B19R deletions (NYVAC-C-ΔB8RB19R) revealed a concerted upregulation of innate immune pathways (IFN-stimulated genes [ISGs]) of increasing magnitude with NYVAC-C-ΔB19R and NYVAC-C-ΔB8RB19R than with NYVAC-C. Deletion of B8R and B19R resulted in an enhanced activation of IRF3, IRF7, and STAT1 and the robust production of type I IFNs and of ISGs, whose expression was inhibited by anti-type I IFN antibodies. Interestingly, NYVAC-C-ΔB8RB19R induced the production of much higher levels of proinflammatory cytokines (tumor necrosis factor [TNF], interleukin-6 [IL-6], and IL-8) than NYVAC-C or NYVAC-C-ΔB19R as well as a strong inflammasome response (caspase-1 and IL-1β) in infected monocytes. Top network analyses showed that this broad response mediated by the deletion of B8R and B19R was organized around two upregulated gene expression nodes (TNF and IRF7). Consistent with these findings, monocytes infected with NYVAC-C-ΔB8RB19R induced a stronger type I IFN-dependent and IL-1-dependent allogeneic CD4(+) T cell response than monocytes infected with NYVAC-C or NYVAC-C-ΔB19R. Dual deletion of type I and type II IFN immune evasion genes in NYVAC markedly enhanced its immunogenic properties via its induction of the increased expression of type I IFNs and IL-1β and make it an attractive candidate HIV vaccine vector. IMPORTANCE: NYVAC is a replication-deficient poxvirus developed as a vaccine vector against HIV. NYVAC expresses several genes known to impair the host immune defenses by interfering with innate immune receptors, cytokines, or interferons. Given the crucial role played by interferons against viruses, we postulated that targeting the type I and type II decoy receptors used by poxvirus to subvert the host innate immune response would be an attractive approach to improve the immunogenicity of NYVAC vectors. Using systems biology approaches, we report that deletion of type I and type II IFN immune evasion genes in NYVAC poxvirus resulted in the robust expression of type I IFNs and interferon-stimulated genes (ISGs), a strong activation of the inflammasome, and upregulated expression of IL-1β and proinflammatory cytokines. Dual deletion of type I and type II IFN immune evasion genes in NYVAC poxvirus improves its immunogenic profile and makes it an attractive candidate HIV vaccine vector.

Sulfitos duplos contendo cobre (I) e um metal de transição M(II) tipo Cu2SO3.M(II)SO3.2H 2O [M(II) = Cu(II), Fe(II), Mn(II) e Cd(II)]: preparação e seletividade na incorporação de M(II)

The metal-catalyzed autooxidation of S(IV) has been studied for more than a century without a consensus being obtained as to reaction rates, rate laws or mechanisms. The main objective in this work was to explore the reaction between Cu(II) and SO2 in the presence of M(II), paying special attention to the formation of double sulfites like Cu2SO3.M(II)SO3.2H 2O. The two principal aspects studied were: i) a new way to prepare double sulfites with high purity degree and the selectivity in the M(II) incorporation during the salt formation.

Dengue: desenvolvimento de ferramentas moleculares e caracterização de cepas virais quanto a inibição da sinalização do Interferon do tipo I (IFN-I)

A infecção pelo vírus da dengue é um problema de saúde pública global que põe em risco cerca de 2,5 bilhões de pessoas no mundo, com uma incidência de 50-100 milhões de casos resultando em cerca de 24.000 mortes por ano. Os mecanismos envolvidos na resposta imune inata atuam imediatamente após o contato do hospedeiro com os antígenos virais, levando à secreção de interferon do tipo I (IFN-I), a principal citocina envolvida na resposta antiviral. Entender como o sistema IFN-I é inibido em células infectadas pelo vírus dengue pode fornecer valiosas informações sobre a patogênese da doença. Propomos neste estudo analisar a inibição da via de sinalização do IFN-I por diferentes cepas isoladas no estado de Pernambuco, assim como o desenvolvimento de um vírus recombinante da dengue expressando a proteína Gaussia luciferase, para estudos futuros de replicação e imunopatogênese. A fim de estudar a via de sinalização do IFN-I, foram selecionadas cepas dos quatro sorotipos de dengue para crescimento, concentração e titulação viral. Foi utilizada a linhagem celular BHK-21-ISRE-Luc-Hygro que expressa o gene firefly luciferase fusionado a um promotor induzido pelo IFN-I (ISRE - Interferon Stimulated Response Element). Observamos que todos os sorotipos em estudo foram capazes de inibir, em diferentes proporções, a resposta ou sinalização do IFN-I. Com o intuito de auxiliar as pesquisas em dengue, desenvolvemos um vírus repórter de dengue expressando o gene repórter da Gaussia luciferase. Células transfectadas com o transcrito in vitro de um dos clones resultou em imunofluorescência positiva, porém não houve recuperação de partículas infectivas. Outros clones deverão ser testados para recuperação de vírus recombinante repórter. Juntos, os dados da caracterização das cepas em estudo e a recuperação de partículas infectivas da construção realizada neste trabalho deverão contribuir para as pesquisas em imunopatogênese, replicação viral e desenvolvimento de antivirais contra o dengue

Expressão das iodotironinas desiodases tipos I e II em diferentes tecidos de camundongos normais e com deficiência inata para a desiodase tipo I

Duas enzimas, as iodotironinas desiodases tipos I e II (D1 e D2), catalizam a reação de 5’ desiodação do T4 promovendo a formação do hormônio tireoidiano ativo, T3. A D1, principal fonte de T3 circulante no plasma, esta presente no fígado, rim e tireóide. Até recentemente, acreditava-se que a expressão da D2 estivesse restrita a tecidos nos quais a concentração intracelular de T3 desempenha um papel crítico como na hipófise, sistema nervoso central e tecido adiposo marrom (TAM). Estes conceitos foram estabelecidos com base em estudos de atividade enzimática em homogenados de tecidos de ratos. A recente clonagem dos cDNAs da D1 e D2, de ratos e humanos, forneceu novos meios para a avaliação da distribuição tecidual e dos mecanismos que regulam a expressão dos genes destas enzimas. Estudos anteriores demonstraram que altos níveis de mRNA da D2 são encontrados na tireóide e músculos cardíaco e esquelético em humanos, entretanto este mesmo padrão não foi observado em ratos. Os hormônios tireoidianos tem um efeito direto sobre as desiodases, regulando a ação dessas enzimas de maneira tecido-específica. Estudos prévios demonstraram que elevados níveis de T4 reduzem à metade a atividade da D2 no cérebro e hipófise dos camundongos C3H/HeJ (C3H), linhagem de camundongos que apresenta uma deficiência inata da D1 compensada com o aumento dos níveis séricos de T4 que, nestes animais, são aproximadamente o dobro daqueles observados nos camundongos normais, C57BL/6J (C57). No presente trabalho, utilizamos a técnica da PCR a partir da transcrição reversa (RT-PCR) para determinar o padrão de expressão do mRNA da D1 e D2 em diferentes tecidos de camundongos e avaliar sua regulação pelos hormônios tireoidianos. Investigamos, também, os níveis de mRNA da D2 em diferentes tecidos de camundongos normais e com deficiência inata da D1 para avaliarmos o mecanismo pelo qual o T4 regula a atividade da D2 nos animais deficientes. Nossos resultados demonstraram, como esperado, que altos níveis de mRNA da D1 estão presentes no fígado e rim e em menores quantidades no testículo e hipófise. Detectamos mRNA da D2, predominantemente, no TAM, cérebro, cerebelo, hipófise e testículo. Níveis mais baixos de expressão foram detectados, também, no coração. O tratamento com T3 reduziu, significativamente, a expressão da D2 no TAM e coração, mas não no cérebro e testículo. Por outro lado, os níveis de mRNA da D2 aumentaram, significativamente, no testículo de camundongos hipotireoideos. Transcritos da D2 foram identificados no cérebro, cerebelo, hipófise, TAM, testículo e, em menores quantidades, no coração em ambas as linhagems de camundongos, C57 e C3H. Entretanto, ao contrário da atividade, nenhuma alteração significativa nos níveis basais de expressão do mRNA da D2 foi detectada nos tecidos dos camundongos deficientes. O tratamento com T3 reduziu de forma similar, os níveis de mRNA da D2 no TAM e coração em ambos os grupos de animais. Em conclusão, nossos resultados demonstraram que o mRNA da D2 se expressa de forma ampla em diferentes tecidos de camundongos, apresentando um padrão de expressão similar ao descrito em ratos. A co-expressão da D1 e D2 no testículo sugere um papel importante dessas enzimas no controle homeostático do hormônio tireoidiano neste órgão. Demonstramos, também, que a deficiência da D1 não altera os níveis basais de expressão do mRNA da D2 nos camundongos C3H, confirmando que o T4 atua ao nível pós-transcricional na regulação da atividade da D2 nestes animais. Além disso, o T3 age de forma tecido-específica e tem efeito similar sobre a regulação pré-transcricional do gene da D2 em ambas as linhagens de camundongos.

Tratamiento de maloclusión classe II división 1 con el aparato de Herbst tipo férula, después del pico de crecimiento puberal

Malocclusion class II-1, is represented by a high prevalence in Brazil, being something common in orthodontic practice. One of the main characteristics of this malocclusion is jaw retrusion, by what many devices of jaw advance are presented in the literature. Being one of them Herbst's device, which is a functional and fixed device created by Emil Herbst (1905) and updated by Hans Pancherz in the decade of 80s.This device is characterized by keeping the jaw advance in a continuous way, while presenting a less active treatment, leading to an immediate aesthetic impact, and the patient cooperation is not required. To improve the anchoring and prevent the collapse of the apparatus was set up last amended version of it by Dr Raveli quoted as Herbst splint. Recent research indicates the use of this device after the peak pubertal growth, creating an appropriate response condylar. The aim of this work is to show the orthodontist a choice of how to use the splint Herbst in Class malocclusions II-1.

Complessi tetrazolici di Ru(II) come fotoassorbitori per celle solari di tipo DSSC

Questo lavoro di tesi sperimentale è stato dedicato alla sintesi di alcuni nuovi complessi tetrazolici di Ru(II) e, in collaborazione con il personale dell’istituto ISTEC-CNR di Faenza, al loro impiego come fotoassorbitori per celle solari di tipo DSSC. L’idea progettuale alla base di questa attività è scaturita dalla volontà di modificare la struttura di due coloranti di riferimento (N719 e N749) sostituendo i gruppi tiocianato (SCN-) coordinati al centro metallico con leganti tetrazolici opportunamente funzionalizzati. In questo elaborato si riporta la descrizione e la discussione dettagliata della sintesi dei complessi, della loro caratterizzazione e delle performances delle celle DSSC contenenti tali complessi come fotoassorbitori.

Interferon-γ Induces Expression of MHC Class II on Intestinal Epithelial Cells and Protects Mice from Colitis

Immune responses against intestinal microbiota contribute to the pathogenesis of inflammatory bowel diseases (IBD) and involve CD4(+) T cells, which are activated by major histocompatibility complex class II (MHCII) molecules on antigen-presenting cells (APCs). However, it is largely unexplored how inflammation-induced MHCII expression by intestinal epithelial cells (IEC) affects CD4(+) T cell-mediated immunity or tolerance induction in vivo. Here, we investigated how epithelial MHCII expression is induced and how a deficiency in inducible epithelial MHCII expression alters susceptibility to colitis and the outcome of colon-specific immune responses. Colitis was induced in mice that lacked inducible expression of MHCII molecules on all nonhematopoietic cells, or specifically on IECs, by continuous infection with Helicobacter hepaticus and administration of interleukin (IL)-10 receptor-blocking antibodies (anti-IL10R mAb). To assess the role of interferon (IFN)-γ in inducing epithelial MHCII expression, the T cell adoptive transfer model of colitis was used. Abrogation of MHCII expression by nonhematopoietic cells or IECs induces colitis associated with increased colonic frequencies of innate immune cells and expression of proinflammatory cytokines. CD4(+) T-helper type (Th)1 cells - but not group 3 innate lymphoid cells (ILCs) or Th17 cells - are elevated, resulting in an unfavourably altered ratio between CD4(+) T cells and forkhead box P3 (FoxP3)(+) regulatory T (Treg) cells. IFN-γ produced mainly by CD4(+) T cells is required to upregulate MHCII expression by IECs. These results suggest that, in addition to its proinflammatory roles, IFN-γ exerts a critical anti-inflammatory function in the intestine which protects against colitis by inducing MHCII expression on IECs. This may explain the failure of anti-IFN-γ treatment to induce remission in IBD patients, despite the association of elevated IFN-γ and IBD.

The performance of interferon-gamma release assays in tuberculosis patients with type II diabetes

The sensitivity of Interferon-γ release assays for detection of Mycobacterium tuberculosis (MTB) infection or disease is affected by conditions that depress host immunity (such as HIV). It is critical to determine whether these assays are affected by diabetes and related conditions (i.e. hyperglycemia, chronic hyperglycemia, or being overweight/obese) given that immune impairment is thought to underline susceptibility to tuberculosis (TB) in people with diabetes. This is important for tuberculosis control due to the millions of type 2 diabetes patients at risk for tuberculosis worldwide.^ The objective of this study was to identify host characteristics, including diabetes, that may affect the sensitivity of two commercially available Interferon-γ (IFN-γ) release assays (IGRA), the QuantiFERON®-TB Gold (QFT-G) and the T-SPOT®.TB in active TB patients. We further explored whether IFN-γ secretion in response to MTB antigens (ESAT-6 and CFP-10) is associated with diabetes and its defining characteristics (high blood glucose, high HbA1c, high BMI). To achieve these objectives, the sensitivity of QFT-G and T-SPOT. TB assays were evaluated in newly diagnosed, tuberculosis confirmed (by positive smear for acid fast bacilli and/or positive culture for MTB) adults enrolled at Texas and Mexico study sites between March 2006 and April 2009. Univariate and multivariate models were constructed to identify host characteristics associated with IGRA result and level of IFN-γ secretion.^ QFT-G was positive in 68% of tuberculosis patients. Those with diabetes, chronic hyperglycemia or obesity were more likely to have a positive QFT-G result, and to secrete higher levels of IFN-γ in response to the mycobacterial antigens (p<0.05). Previous history of BCG vaccination was the only other host characteristic associated with QFT-G result, whereby a higher proportion of non-BCG vaccinated persons were QFT-G positive, in comparison to vaccinated persons. In a separate group of patients, the T-SPOT.TB was 94% sensitive, with similar performance in all tuberculosis patients, regardless of host characteristics.^ In summary, we have demonstrated the validity of QFT-G and T-SPOT. TB to support the diagnosis of TB in patients with a range of host characteristics, but most notably in patients with diabetes. We also confirmed that TB patients with diabetes and associated characteristics (chronic hyperglycemia or BMI) secreted higher titers of IFN-γ when stimulated with MTB specific antigens, in comparison to patients without these characteristics. Together, these findings suggest that the mechanism by which diabetes increases risk to TB may not be explained by the inability to secrete IFN-γ, a key cytokine for TB control.^

Efficient recruitment of TFIIB and CBP-RNA polymerase II holoenzyme by an interferon-β enhanceosome in vitro

The transcriptional activity of an in vitro assembled human interferon-β gene enhanceosome is highly synergistic. This synergy requires five distinct transcriptional activator proteins (ATF2/c-JUN, interferon regulatory factor 1, and p50/p65 of NF-κB), the high mobility group protein HMG I(Y), and the correct alignment of protein-binding sites on the face of the DNA double helix. Here, we investigate the mechanisms of enhanceosome-dependent transcriptional synergy during preinitiation complex assembly in vitro. We show that the stereospecific assembly of the enhanceosome is critical for the efficient recruitment of TFIIB into a template-committed TFIID-TFIIA-USA (upstream stimulatory activity complex) and for the subsequent recruitment of the RNA polymerase II holoenzyme complex. In addition, we provide evidence that recruitment of the holoenzyme by the enhanceosome is due, at least in part, to interactions between the enhanceosome and the transcriptional coactivator CREB, cAMP responsive element binding protein (CBP). These studies reveal a unique role of enhanceosomes in the cooperative assembly of the transcription machinery on the human interferon-β promoter.

Contribuição para o estudo dos Rhinotragini (Coleoptera, Cerambycidae). II. Revisão de Ommata White, 1855

O gênero Ommata é revisto e dividido em quatro gêneros: Ommata sensu strictu, Acatainga gen. nov. (espécie-tipo Odontocera (?) maia Newman, 1841), Etimasu gen. nov. (espécie-tipo Ommata cosmipes Peñaherrera-Leiva & Tavakilian, 2003) e Pyrpotyra gen. nov. (espécie-tipo Ommata (Ommata) paradisiaca Tippmann, 1953). São descritas cinco espécies novas provenientes do Brasil e Bolívia: Ommata nigricollis (Brasil, Espírito Santo), O. andina (Bolívia), Pyrpotyra pytinga (Brasil, Pará), P. capixaba (Brasil, Espírito Santo) e P. paraensis (Brasil, Pará). As seguintes espécies são transferidas de Ommata para os novos gêneros, além das espécies-tipos: Acatinga boucheri (Tavakilian & Peñaherrera-Leiva, 2005), comb. nov.; A. gallardi (Peñaherrera-Leiva & Tavakilian, 2004), comb. nov.; A. quinquemaculata (Zajciw, 1966), comb. nov.; Pyrpotyra albitarsis (Galileo & Martins, 2010), comb. nov.

Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin

Chronic hepatitis C is often a progressive, fibrotic disease that can lead to cirrhosis and other complications. The recommended therapy is a combination of interferon and ribavirin. Besides its antiviral action, interferon is considered to have antifibrotic activity. We examined the outcome of hepatic fibrosis and inflammation in chronic hepatitis C patients who were non-responders to interferon. We made a case series, retrospective study, based on revision of medical records and reassessment of liver biopsies. For inclusion, patients should have been treated with interferon alone or combined with ribavirin, with no virological response (non responders and relapsers) and had a liver biopsy before and after treatment. Histological evaluation included: i-outcome of fibrosis and necroinflammation; ii-annual fibrosis progression rate evaluation, before and after treatment. Seventy-five patients were included. Fifty-seven patients (76%) did not show progression of fibrosis after treatment, compared to six (8%) before treatment (p < 0.001). The mean annual fibrosis progression rate was significantly reduced after treatment (p = 0.036). Inflammatory activity improved in 19 patients (25.3%). The results support the hypothesis of an antifibrotic effect of interferon-based therapy, in non-responder patients. There was evidence of anti-inflammatory effects of treatment in some patients.